Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Response deadline
- Nov 17, 2026 Due in 72 days
- Date posted
- Nov 18, 2024
- Source
- Open notice
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.
Classifications
- NAICS93.393
Documents (1)
- DownloadPAR-25-096-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)Due Sep 18, 2026
- Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)Due Jul 5, 2029
- Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)Due Sep 7, 2028
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)Due Sep 10, 2027
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)Due Oct 8, 2027
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)Due Jan 7, 2027